How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?

• Published in: Vaccine Vol. 37; no. 34; pp. 4778 - 4783
• Main Authors: Giersing, Birgitte K., Porter, Chad K., Kotloff, Karen, Neels, Pieter, Cravioto, Alejandro, MacLennan, Calman A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 07.08.2019; Elsevier Limited
• Subjects: Age; Allergy and Immunology; Antigens; Antigens, Bacterial - chemistry; Antigens, Bacterial - immunology; Candidates; Challenge; Child; Cholera; Clinical Trials as Topic; Congresses as Topic; Development; Diarrhea - epidemiology; Diarrhea - immunology; Diarrhea - microbiology; Diarrhea - prevention & control; Dysentery, Bacillary - epidemiology; Dysentery, Bacillary - immunology; Dysentery, Bacillary - microbiology; Dysentery, Bacillary - prevention & control; enterotoxigenic Escherichia coli; FDA approval; Host-Pathogen Interactions - immunology; human diseases; Humans; Immunization - methods; Immunogenicity, Vaccine; Infectious diseases; issues and policy; Licenses; Licensure - ethics; Licensure - legislation & jurisprudence; Models, Immunological; Pathogenesis; Policy; Product development; Public health; Shigella; Shigella - drug effects; Shigella - immunology; Shigella - pathogenicity; Shigella Vaccines - administration & dosage; Shigella Vaccines - biosynthesis; stakeholders; Typhoid; Vaccine; Vaccines; Vaccines, Conjugate; Viruses; United States > US; Policy; Development; Vaccine; Shigella; Challenge

Controlled Human Infection Models (CHIMs) now exist for several infectious diseases. CHIMs offer significant insight into disease pathogenesis, as well the potential to rapidly test clinical proof-of-concept of vaccine candidates. The application of CHIMs to identify a correlate of protection that m...